

## **OncoMed Pharmaceuticals Inc**

### **COMPANY AND PIPELINE OVERVIEW REPORT**

Coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 07-Feb-2013

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drugs..... 11

[Return to Table of Contents](#)

# OncoMed Pharmaceuticals Inc

## COMPANY OVERVIEW

Company Name	OncoMed Pharmaceuticals Inc
Parent Company Name	OncoMed Pharmaceuticals Inc
Website	<a href="http://www.oncomed.com/">http://www.oncomed.com/</a>
Country	US
Number of Drugs in Active Development	8
Number of Inactive Drugs	0
Number of Patents as Owner	29
Number of Patents as Third Party	1
Number of Deals	10
Key Indications	Cancer,Solid tumor,Pancreas tumor,Colorectal tumor,Breast tumor,Lung tumor,Non-small-cell lung cancer,Prostate tumor,Head and neck tumor,Melanoma
Key Target-based Actions	Delta-like protein ligand 4 inhibitor,VEGF receptor antagonist,Notch-1 receptor antagonist,Notch receptor modulator,Frizzled-7 receptor antagonist,Frizzled-8 receptor antagonist,Leucine rich repeat containing protein modulator,Notch-2 receptor antagonist,Notch-3 receptor antagonist,RSPO gene modulator
Key Technologies	Biological therapeutic,Infusion,Intravenous formulation,Parenteral formulation unspecified,Monoclonal antibody humanized,Monoclonal antibody,Small molecule therapeutic,Monoclonal antibody human,Immunoglobulin-G,Drug combination

## COMPANY PROFILE

### SUMMARY

OncoMed, established in 2004 and headquartered in Mountain View, CA, is a biotechnology company that discovers and develops mAbs and small molecules targeting biological pathways to destroy cancer stem cells.

### LICENSING AGREEMENTS

In January 2010, OncoMed Pharmaceuticals and Fluidigm Corporation agreed to apply Fluidigm's microfluidic tools to the analysis of tumor cell heterogeneity. Financial details were undisclosed.

In June 2006, MorphoSys granted OncoMed Pharmaceuticals access to HuCAL GOLD antibody therapy use in cancer drug discovery programs. The agreement included an upfront payment and annual user fees. In June 2008, OncoMed exercised its option to extend its license agreement for MorphoSys' HuCAL GOLD antibody library and initiated development of two cancer stem cell therapeutic antibody programs.

### EARLY R&D

In June 2010, Bayer Schering Pharma and OncoMed Pharmaceuticals were collaborating on the discovery, development and commercialization of cancer stem cell-based, Wnt signaling pathway-targeting, anticancer antibody, peptide, and small molecule therapeutics; the research would potentially include five compounds, including OncoMed's lead candidate OMP-18R5. Bayer also took on an additional project to discover and develop further anti-Wnt signalling small molecule therapeutics.

### FINANCIAL

In May 2012, OncoMed planned to raise \$115 million from an IPO of its shares. The company would be listed on the NASDAQ under the ticker symbol 'OMED'.

In November 2008, OncoMed completed the final \$93 million tranche of its series B financing round. A total of \$154 million was raised from the financing.

In September 2005, OncoMed raised \$13.9 million in a series A preferred stock financing.

[Return to Table of Contents](#)




## PRODUCT PORTFOLIO SUMMARY

### DRUGS

#### Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	8	0	8
Gastrointestinal disease	2	0	2
Respiratory disease	1	0	1

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	2
Phase 1 Clinical	3
Discovery	3

[Return to Table of Contents](#)

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	0	0	2	0	2
Drug - Funding	1	0	0	0	1
Drug - Early Research/Development	0	0	1	0	1
Drug - Development/Commercialization License	2	0	0	0	2
Drug - Manufacturing/Supply	0	0	1	0	1
Drug - Development Services	0	0	1	0	1
Technology - Delivery/Formulation	0	0	1	0	1
Technology - Target Validation	0	0	1	0	1

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	8	10
Gastrointestinal disease	3	3
Respiratory disease	1	1
Hematological disease	1	1
Immune disorder	1	1

### Trials by Phase

Phase	Ongoing	All
Phase 2	1	1
Phase 1	7	9

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)





## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	2	1	3
Endocrine disease	15	1	16
Gastrointestinal disease	15	1	16
Genitourinary disease	12	1	13
Growth disorder	0	1	1
Hematological disease	2	1	3
Degeneration	0	1	1
Andrology	8	1	9
Immune disorder	2	2	4
Psychiatric disorder	0	1	1
Musculoskeletal disease	0	2	2
Neoplasm	29	1	30
Ocular disease	0	1	1
Genetic disorder	0	1	1
Metabolic disorder	0	1	1
Mouth disease	0	1	1
Neurological disease	0	2	2
Nutritional disorder	0	1	1
Respiratory disease	11	1	12
Infectious disease	0	1	1
Injury	0	1	1
Inflammatory disease	0	2	2
Otorhinolaryngological disease	0	1	1
Gynecology and obstetrics	15	1	16
Dermatological disease	5	1	6

[Return to Table of Contents](#)

Ulcer	0	1	1
-------	---	---	---

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### OMP-59R5

<b>Drug Name</b>	OMP-59R5
<b>Key Synonyms</b>	
<b>Originator Company</b>	OncoMed Pharmaceuticals Inc
<b>Active Companies</b>	OncoMed Pharmaceuticals Inc, GlaxoSmithKline plc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Pancreas tumor, Solid tumor
<b>Target-based Actions</b>	Notch-2 receptor antagonist, Notch-3 receptor antagonist
<b>Other Actions</b>	Anticancer monoclonal antibody
<b>Technologies</b>	Monoclonal antibody human, Biological therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	21-Nov-2012

### OMP-52M51

<b>Drug Name</b>	OMP-52M51
<b>Key Synonyms</b>	
<b>Originator Company</b>	OncoMed Pharmaceuticals Inc
<b>Active Companies</b>	GlaxoSmithKline plc, OncoMed Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	Notch-1 receptor antagonist
<b>Other Actions</b>	Anticancer monoclonal antibody
<b>Technologies</b>	Monoclonal antibody humanized, Biological therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	24-Dec-2012

[Return to Table of Contents](#)

## demcizumab

<b>Drug Name</b>	demcizumab
<b>Key Synonyms</b>	demcizumab
<b>Originator Company</b>	OncoMed Pharmaceuticals Inc
<b>Active Companies</b>	OncoMed Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Non-small-cell lung cancer, Solid tumor, Pancreas tumor, Colorectal tumor
<b>Target-based Actions</b>	Delta-like protein ligand 4 inhibitor, Notch receptor modulator
<b>Other Actions</b>	Anticancer monoclonal antibody, Angiogenesis inhibitor
<b>Technologies</b>	Monoclonal antibody humanized, Immunoglobulin-G, Intravenous formulation, Infusion, Biological therapeutic
<b>Last Change Date</b>	03-Jan-2013

## OMP-18R5

<b>Drug Name</b>	OMP-18R5
<b>Key Synonyms</b>	
<b>Originator Company</b>	OncoMed Pharmaceuticals Inc
<b>Active Companies</b>	OncoMed Pharmaceuticals Inc, Bayer Schering Pharma AG
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	Frizzled-7 receptor antagonist
<b>Other Actions</b>	Anticancer monoclonal antibody, Stem cell inhibitor
<b>Technologies</b>	Monoclonal antibody, Intravenous formulation, Infusion, Biological therapeutic
<b>Last Change Date</b>	24-Dec-2012

[Return to Table of Contents](#)

**OMP-54F28**

<b>Drug Name</b>	OMP-54F28
<b>Key Synonyms</b>	
<b>Originator Company</b>	OncoMed Pharmaceuticals Inc
<b>Active Companies</b>	Bayer Schering Pharma AG, OncoMed Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Solid tumor, Cancer
<b>Target-based Actions</b>	Frizzled-8 receptor antagonist
<b>Other Actions</b>	Anticancer
<b>Technologies</b>	Intravenous formulation, Infusion, Biological therapeutic
<b>Last Change Date</b>	13-Jul-2012

**anti-DLL4/VEGF bispecific mAb (cancer), Oncomed**

<b>Drug Name</b>	anti-DLL4/VEGF bispecific mAb (cancer), Oncomed
<b>Key Synonyms</b>	
<b>Originator Company</b>	OncoMed Pharmaceuticals Inc
<b>Active Companies</b>	OncoMed Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	VEGF receptor antagonist, Delta-like protein ligand 4 inhibitor
<b>Other Actions</b>	Anticancer protein kinase inhibitor, Anticancer monoclonal antibody
<b>Technologies</b>	Monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	23-Nov-2012

[Return to Table of Contents](#)

### Wnt signalling pathway targeted small molecules (cancer), Oncomed/Bayer Schering Pharma

<b>Drug Name</b>	Wnt signalling pathway targeted small molecules (cancer), Oncomed/Bayer Schering Pharma
<b>Key Synonyms</b>	
<b>Originator Company</b>	OncoMed Pharmaceuticals Inc
<b>Active Companies</b>	Bayer Schering Pharma AG, OncoMed Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	
<b>Other Actions</b>	Anticancer
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	09-Mar-2012

### RSPO-LGR pathway modulators (cancer), Oncomed

<b>Drug Name</b>	RSPO-LGR pathway modulators (cancer), Oncomed
<b>Key Synonyms</b>	
<b>Originator Company</b>	OncoMed Pharmaceuticals Inc
<b>Active Companies</b>	OncoMed Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	RSPO gene modulator, Leucine rich repeat containing protein modulator
<b>Other Actions</b>	Anticancer protein kinase inhibitor
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	09-Mar-2012

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

